This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Should You Hold Onto Anthem (ANTM) in Your Portfolio?
by Zacks Equity Research
A solid positioning in an ever-growing industry along with strong fundamentals make Anthem (ANTM) a good fit for investment gains.
Magellan (MGLN) Unit Launches Solution to Improve Behavioral Care
by Zacks Equity Research
Magellan's (MGLN) unit - Magellan Healthcare - together with NeuroFlow, introduces a collaborative care management solution in a bid to ease the behavioral health treatment process.
Why Should You Hold Molina Healthcare (MOH) in Your Portfolio?
by Zacks Equity Research
Riding high on strategic measures and membership growth, Molina Healthcare (MOH) holds enough potential to reap benefits for investors.
Cigna's (CI) 2022 Expansion Plans to Boost MA Customer Base
by Zacks Equity Research
Cigna (CI) unveils enhanced health plans for its customers to opt for in the 2022 Medicare AEP period. The company will foray into newer counties and states to offer enhanced health outcomes.
Here's Why You Should Retain Cigna (CI) Stock for Now
by Zacks Equity Research
Cigna (CI) is benefiting on the back of robust segmental performances and well-diversified healthcare suite. A strong partner network throughout U.S. is an added advantage.
UnitedHealth (UNH) Unit to Offer Better Pharmacy Care in Arizona
by Zacks Equity Research
Genoa, which comes under UnitedHealth Group's (UNH) subsidiary Optum, opens a pharmacy in one of Arizona's clinics for offering enhanced pharmacy care for behavioral health patients.
Humana (HUM), Kelsey-Seybold Clinic Tie Up for Better Healthcare
by Zacks Equity Research
Humana (HUM) inks a deal with Kelsey-Seybold Clinic in Houston to offer its Humana Medicare Advantage HMO members enriched healthcare facilities.
Why Should You Hold Centene (CNC) in Your Portfolio Now?
by Zacks Equity Research
Riding high on strategic initiatives and operational excellence, Centene (CNC) holds potential to reap benefits for investors.
Humana (HUM), Curant Health Team Up to Aid Chronic Patients
by Zacks Equity Research
Humana (HUM) inks a deal with Curant Health to offer its members with chronic diseases enriched healthcare facilities.
Here's Why You Should Hold Molina Healthcare (MOH) Stock Now
by Zacks Equity Research
Riding high on its rising membership, a healthy revenue stream and restructuring measures, Molina Healthcare (MOH) holds potential to reap benefits for investors.
Encompass Health (EHC) Opens Hospital, Boosts Florida Footprint
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Pensacola, FL aimed at providing improved health outcomes across the state.
Why Should You Hold onto Anthem (ANTM) in Your Portfolio?
by Zacks Equity Research
Riding high on growing revenues, solid guidance and strategic initiatives, Anthem (ANTM) holds potential to reap benefits for investors.
Cigna (CI) Hikes Buyback Authorization, Boosts Shareholder Value
by Zacks Equity Research
Cigna's (CI) board raises share buyback authorization in an effort to support prudent capital deployment.
Humana (HUM) Acquires Remaining Shares at Kindred at Home
by Zacks Equity Research
Humana (HUM) closes its Kindred at Home buyout to bolster its home health and hospice business.
The Joint Corp. (JYNT) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
The Joint Corp. (JYNT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Joint Corp. (JYNT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 260.00% and 15.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
The Joint Corp. (JYNT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
The Joint Corp. (JYNT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Joint Corp. (JYNT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) to Announce Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Humana's (HUM) second-quarter earnings results to reflect a steep expense level, partly offset by better revenues.
What's in the Cards for Centene's (CNC) Earnings in Q2?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect escalated expenses, partly offset by improved revenues.
UnitedHealth (UNH) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
UnitedHealth's (UNH) Q2 revenues are likely to have grown on higher membership. Nevertheless, COVID-related costs and steep expenses due to investment in growth and innovation might have hurt earnings.
3 Health Insurers Poised to Beat Earnings Estimates in Q2
by Srijita Guha
Health insurers' second-quarter 2021 earnings results are likely to reflect higher premiums, partly offset by elevated operating costs.
Anthem (ANTM) Buys MMM & Other Units From InnovaCare Health
by Zacks Equity Research
Anthem (ANTM) purchases subsidiaries of InnovaCare Health to facilitate better health outcomes across Puerto Rico.
Acadia Healthcare (ACHC) Forms JV to Serve Southwest Michigan
by Zacks Equity Research
Acadia Healthcare (ACHC) partners with Bronson Healthcare with an aim to provide enhanced behavioral outcomes across Battle Creek, Kalamazoo and the neighboring communities of Michigan.
Centene (CNC) Offers Senior Notes Priced at $1.8 Billion
by Zacks Equity Research
Centene (CNC) exhibits prudence in issuing notes to procure funds for executing the transaction of its Magellan Health acquisition.